PharmaMar and Boryung Pharm sign a licensing agreement for Zepsyre in Korea
Madrid, November 7th, 2017 - PharmaMar (MSE:PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), if...





